Phase 3 Readout~month

Phase 3 Topline: A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Exp

Indication
Myelofibrosis

Other upcoming events for KPTI

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenan
Patent ExpiryPatent/Exclusivity Expiry: NINLARO
Patent ExpiryPatent/Exclusivity Expiry: VONJO
Patent ExpiryPatent/Exclusivity Expiry: TREANDA
Patent ExpiryPatent/Exclusivity Expiry: BELRAPZO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Exp — KPTI Phase 3 Readout | BioSniper